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Summary: Nuinerous studies have indicated a role of epidermal growth factor in the maintenance of the
gastrointestinal mucosa.
In the present study epidermal growth factor concentrations in saliva and gastric juice of patients with gastric
or duodenal ulcer or gastritis are compared with those of healthy controls. For this purpose a novel ELISA
System has been developed and shown to be sensitive and specific.
It is demonstrated that gastric juice and saliva of patients with gastric ulcer contain less epidermal growth
factor than the samples of healthy controls (p < 0.01). Epidermal growth factor concentrations and Outputs
(product of epidermal growth factor concentration and the volume secreted in 15 min) in the gastric juice of
patients with duodenal ulcer do not differ frona those of healthy controls.
Introduction ,. , , , . , , , , . .
and sahvary glands, the parotid gland being the major
Epidermal growth factor is a single^chain polypeptide source of synthesis and secretion (4).
of Mr 6000 consisting of 53 amino acids (l, 2). Epi- 1 6 role of epidermal growth factor in the pathogen-
dermal growth factor produces a varfety of biological
 esis Of gastrointestinal ulcer disease has received much
responses including euhanced proliferation and dif- attention in the past few years. The "rediscovery" of
ferentiation of epithelial tissues in vivo and in vitro. Campylobacter pylori demonstrates that the "ulcer
Numerous target structures and different modes of discussion" is still controversial (5). The purpose of
action reveal similarities between epidermal growth
 the ^ study is the further elucidation of the
factor and polypeptide hprmones such äs insulin (3). possible involvement of epidermal growth factor in
Epidermal growth factor has been detected in almost ulcer disease-
all body fluids, whef eas synthesis in man has so far High concentrations of epidermal growth factor have
only been shown in Brunner glands of the duodenum been known for a long time to inhibit gastric secretion
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(6). Apart from this artificial effect, many fmdings
suggest that it participates in the maintenance of the
gastrointestinal mucosa (7, 8). These studies, however,
are based on animal models. The earliest data on the
concentration of epidermal growth factor in the saliva
of patients with gastrointestinal ulcer, compared with
healthy controls, were reported by Ohmura et al. (9).
As these results could not be confirmed in our inves-
tigations, definite evidence is still lacking that epider-
mal growth factor in human gastrointestinal ulcer
disease is subject to any alteration.
The present study was performed in order to examine
epidermal growth factor concentrations in saliva and
gastric juice of patients with gastrointestinal com-
plaints (gastric ulcer, duodenal ulcer, gastritis) and
healthy controls. The use of a sensitive, specific and
practicable assay System for routine measurement is
a prerequisite, in order to establish the pathophysiol-
ogical role or even clinical relevance of epidermal
growth factor in various body fluids. In this paper we
present the development of a novel ELISA for human
epidermal growth factor, which involves some unusual
processing stages. This assay is less time-consuming
than any comparable assay published, and it meets
all requirements mentioned above.
Materials and Methods
Reagents
Goat-IgG F(ab')2: anti mouse-IgF (Fc) was obtained from
Jackson, Dianova, Hamburg, FRG; human epidermal growth
factor (human urine), rabbit anti mouse-epidermal growth fac-
ton streptavidin-peroxidase1) from Calbiochem, Frankfurt,
FRG; rabbit serum from Gibco, Karlsruhe, FRG; NHS-LC-
biotin (N[6-(biotinamido)hexanoyloxy]sulphosuccinimide)
from Pierce, Oud Beijerland, Netherlands; 3,3',5,5'-tetrame-
thylbenzidine (TMB) from Fluka, Buchs, Switzerland; mouse
monoclonal anti human-epidermal growth factor antibodies
from AMGEN, Thousand Oaks, California, USA.
Rabbit anti human-epidermal growth factor antiserum was
kindly provided by Dr. H. Gregory, ICI, Macclesfield, UK.
was used before sample withdrawal. The endoscopies were
performed for sound medical reasons and not for the purpose
of the present investigation.
Total 15 minutes Output could be measured by aspiration, using
gastric tubes (UNO) that were placed in the antrum under X-
ray control.
Epidermal growth factor concentration was measured in gastric
juice of patients with acute gastric ulcers (n = 9), gastric ulcers
under treatment (2 40 mg/d famotiäin) (n = 9), duodenal
ulcers (n = 14), gastritis (n = 22) and healthy controls (n = 19).
The 15-minute^output of epidermal growth factor was deter-
mined in the gastric juice of patients with treated gastric ulcer
(n = 8), duodenal ulcer (n = 6), gastritis (n = 7) and healthy
controls (n = 14).
Saliva (2—3 ml) was collected without Stimulation before en-
doscopic examination from patients with gastrie ulcer (treated
and untreated) (n = 11), patients with duodenal ulcer (n = 4),
and patients with gastritis (n = 10). Total saliva secretion in
deflned periods could not be ascertained due to the disturbance
and Interruption of routine endoscopy. Saliva samples and 15-
minute gastric juice volumes were collected from the same
patients who underwent sample collection during endoscopic
examination. Patients with acute gastric ulcer and with ulcer
under treatment were different individuals. For saliva exami-
nation gastric ulcer patient groups were not sepairated intq
acute and treated gastric ulcer.
All diagnoses were confirmed by endoscopy and histology. In
the case of patients with treated ulcers, samples were collected
during control endoscopy or after control endoscopy (for out-
put-determination), respectively.
All samples were centrifuged at 15000g for 5 minutes and
stored at -40 °C untü use.
Biotinylated immunoglobulins
Immunoglobulin fractions were prepared from whole antisera
by repeated ammonium sulphate precipitation at 0.40 Satura-
tion. After redissolving the pellet in distilled water, the sample
was desalted by chromatography on Sephadex G-25 fine, equi-
librated with 0.015 mol/1 södium phosphate, pH 7.4. The pro-
tein concentration of the eluate was determined according to
Bradford (10).
Immunoglobulins in 0.015 mol/1 phosphate buffer, pH 7.4, were
incubated with NHS-LC-biotin (molar ratio of biotin to IgG
approximately 30:1) for three days at 6 °C. The mixture was
then diluted with l volume ethylene glycol and stored at
-20 °C.
Equipments
Microtitre plates, high binding capacity, from Nunc, Wiesba-
den, FRG and a Titertek Multiscan photometer from Flow
Laboratories Meckenheim, FRG connected to an Epson HX
20 were used.
Samples and patient collectives
Saliva, gastric juice and spontaneous urine were collected from
healthy volunteers and patients between 07.00 and 11.30 AM
after a fasting period of 12 hours. Patients discontinued the use
of drugs 36 hours before exammation. Samples of gastric juice
were obtained by aspirating 2 —3 ml through a sample collector
using the Instrument channel of the endoscope. No lavage fluid
*) Enzymes: Horseradish peroxidase (donor: hydrogen peröxide
oxidoreductase, EC 1.11.1.7).
Epidermal growth factor-ELISA
Microtitre-plates were coated by adding 150 of a 1:250
dilution (v/v) goat-F(ab')2 anti mouse-IgG (Fc) in 0.015 mol/i
phosphate buffer, pH 7.4. After 2 hours, the microtitre plates
were washed 3 with wash buffer (0.015 mol/l phosphate
buffer, pH 7.4 containing l g/l fween 20) and l with distilled
water, vacuum-dried and stored desiccated at 4 °C for up to 6
months.
Standards at 0.05, 0.1, 0.2, 0.5, l and 2 ^/1 in assay buffer .(10
ml/l rabbit serum in wash buffer) were prepared daily from a
10 mg/1 stock human epidermal growth factor solution in eth-
ylene glycol volume fraction 0.50 stored in aliquote at —20 °C.
Serum samples were used undiluted; saliva ät ä l: 2 dilution,
urines at a l: 50 and a l: 500 (v/v) dilution in assay buffer;
gastric juice at a 1:2 (v/v) dilution in 0.15 inöl/1 phosphate
buffer, pH 7.4 (which adjusts the pH of the gastric juice to
above 7.0).
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For the assay, 60 μΐ of Standard or sample were placed in
duplicate into consecutive wells of a coated microtitre plate.
An 8 h incubation period at room temperature was started by
adding 90 μΐ of an antibody mixture containing the monoclonal
anti epidermal growth factor at a l: 90 000 dilution and the
biotinylated rabbit anti epidermal growth factor at a l: 9000
dilution in assay buffer.
After 2 washes, 150 μΐ streptavidin-peroxidase at a 1:5000
dilution in assay bufter were added for 30 min.
After 6 washes, 150 μΐ tetramethylbenzidine Substrate solution
in pH 3.95 citrate/H2O2 buffer (11) were added and left for 10
min. The reaction was stopped by addition of 50 μΐ 2 mol/1
sulphuric acid and the absorbance read at 450 and 492 nm
(measuring and reference wavelength, respectively).
The test scheme is illustrated in figure l.
Statistical analysis
Statistical differences were evaluated by the U-test according
to Wilcoxon, Mann & Whitney (12).
Results
Our new ELISA procedure yields a linear Standard
curve with epidermal growth factor concentrations up
to 2 μ§/1 (fig. 2). The lower detection limit of epider-
mal growth factor in body fluids can be considered
to be approximately 20 ng/1 (determined by calculat-
ing the mean ± 3 SD of 8 replicate measurements of
the zero sample). Within the measuring r nge (0.02—
2 μg/l) the maximal intra- and interassay imprecision
was 5% and 9%, respectively.
As an indication of test linearity, the dilution curves
of different sample materials are demonstrated in
figure 3. The coefficient of correlation (r) of the di-
lutions l: 32 to l: 2 with their measured concentra-
tions is 0.97.
When defined amounts of epidermal growth factor
were added to different sample material, the recovery
was 92%-103% (tab. 1).
No sex or age-dependent differences in epidermal
growth factor concentration were noticed in saliva or
gastric juice of healthy controls.
Four healthy volunteers endured our "thirst-experi-
ments" in which 5-minute-saliva-samples were col-
lected at 08.00 AM after 12 hours thirst/fasting pe-
riod. After another 4 hours period a second 5-minute-
saliva-sample was obtained. Thirty minutes after
water Substitution (0.71 mineral water following a
thirst/fasting period lasting over 16 h) a third 5-min-
ute-saliva-sample was obtained from the volunteers.
The results suggest that concentrations of epidermal
growth factor in saliva increase after longer thirst/
fasting periods and descend to approximately half
their original values after water Substitution (tab. 2).
The calculated Output of epidermal growth factor and
the ratio of epidermal growth factor concentration to
the concentration of total protein seem to be nearly
constant during thirst and after water Substitution.
B
Fig. 1. Schematic representation of the human epidermal growth factor ELISA.
A. First incubation with mouse monoclonal anti human epidermal growth factor, Standard/sample, biotin-conjugated
fabbit polyclonal anti human epidermal growth factor.
B. Assay System after the washing cycles before addition of avidin-peroxidase.
= goa,t anti mouse IgG (Fc).
= mouse monoclonal anti human epidermal growth factor.
= human epidermal growth factor.
= rabbit polyclonal anti human epidermal growth factor.
= biotin.
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Fig. 2. Epidermal growth factor Standard curve.
Plot of absorbance (450 nm) of different Standard dl·
lutions against concentration. All values are mean of
duplicate measurements. The coefficient of Variation is
less than 4%.
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Fig. 3. Epidermal growth factor concentration in sample dilu-
tion.
Plot of concentrations at different dilutions of various
body fluids against numeric dilution. Good linearity
(r > 0.97) is obtained from l: 2 to l: 32 dilution. Con-
centrations in undiluted (1:1) samples are decreased
due to low pH or high sample viscosity.
o = Saliva
O = Saliva
Q = Duodenal juice
Tab. l. Concentrations of epidermal growth factor in gastric
juice (l: 2 in 0.15 mol/1 phosphate buffer, pH 7.4), saliva
(l: 2 in 0.015 mol/1 phosphate buffer, pH 7.4) and seruni
before and after addition of 3 and 6 μΐ epidermal growth
factor Standard solution (16 μg/l) to 200 μΐ sample.
Epidermal growth factor [ng/1]
Ο μΐ added
Found
3 μΐ added 6 μΐ added
Calcu-
lated
Found Calcu-
lated
Found
Gastric juice 540
Sa va 1290
Serum 130
776 720 1006 980
1526 1480 1756 1690
366 370 596 610
Tab. 2. Epidermal growth factor concentration, ratio of epi-
dermal growth factor concentratipn to total protein
concentration and prod ct of co centration and vol-
uine ("output") in saliva samples, collected over a pe-
riod of 5 minutes from 4 probands after thirst/fasting
periods f 12 and 16 hours and after water Substitution
(mean ± SD).
Epidermal grpwth factor
|jig/g protein] [ng/5 min]
Thirst (12 h)
Thirst (16 h)
Water
Substitution
3.0 ± 0.7
3.8 + 0.8
1.5 -1- 0.4
7.9 ± 1.1
7.7 ± 1,3
6.8 + 0.9
6,9 ± 1.2
6.1 + 1.0
5.7 ± 1.4
Tab. 3. Concentrations of epidermal growth factor in saliva
and ratio of epidermal growth factor concentration to
total protein concentration (mean ± SD).
Epidermal growth factor
Controls
Gastric ulcer
Duodenal ulcer
Gastritis
n
12
11
4
10
Dig/11
3.72 ± 1.63
2.25 ± 1.64
3.14 ± 1.25
4.28 ± 1.86
fag/g protein]
5.50 ± 0.80
2.46 ± 1.02**
4.30 ± 0.60
5.62 + 1.40
= p < 0.01 compared with all other groups
No significant differences were noticed in epidermal
growth factor concentrations in saliva. The group of
gastric ulcer patients, however, showed decreased ra-
tios of epidermal growth factor concentratipn to the
concentration of total protein (p < 0.01 compared
with healthy control) (tab. 3 and fig. 5).
Results of gastric juice measurements are demon-
strated in table 4 and figure 4. A significant difference
in epidermal growth factor concentration and 15-
minute-output was seen between gastric ulcer patients
and healthy controls (p < 0.01).
The 15-minute Output of epidermal growth factor in
patients with gastric ulcer was 5 tirnes lower,.and the
epidermal growth factor eoncentration was even 10
times lower than in controls. The values for patients
with duodenal ulcer or gastritis did not differ from
those of the control group.
The amounts of epidermal growth factor excreted in
the urine, based n creatinine, did not differ signifi-
cantly between the examined collectives.
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Tab. 4 Epidermal growth factor concentrations and 15 min Output in gastric juice of control group and patients (mean ± SD).
Epidermal growth factor
** = p < 0.01 compared with healthy controls.
[ng/15 min]
Healthy probands
Acute gastric ulcer
Treated gastric ulcer
Duodenal ulcer
Gastritis
1.19 ± 0.8
0.14 ± 0.08
0.16 ± 0.14
0.90 + 0.58
1.38 ± 1.0
(n = 19)
(n= 9)**
(n= 9)**
(n = 14)
(n = 22)
26.4 ± 15.3
not determined
4.80 + 3.9
25.5 + 23.3
28.2 + 5.6
(n = 14)
(n= 8)**
(n= 6)
(n= 7)
2.5
2 2.0
fe
3 1.5
£
-S 0.5
•a
0.0
.1 50
| 40
l
° 30
f
f 20
σ*
o 10
l
l- n
**
untreated treated
n=19 n = 9 n = 9 n=14 n=22
Control ulfu.s .. .Ulc.us. Gastritis
ventnculi duodeni
treated
n=14 n=8 n=6 n=7
Fig. 4. Epidermal growth factor concentration and Output in
gastric juice.
Concentrations (a) and Outputs (b) of the examined
groups show a clear decrease in patients with gastric
ulcer, whereas duodenal ulcer and gastritis afe not ac-
companied by a decrease of epidermal growth factor in
gastric juice.
All values are means ± SD.
** = p < 0.01 compared with healthy control.
Discussion
We have develpped an ELISA for the measurernent
of epidermal growth factor in body fluids, which has
certain advantages, such s shorter incubation time,
economical consumption of antibodies (1:150000
and l: 15ΌΟΟ final dilution of monoclonal and poly-
clonal antibodies, respectively) and high sensitivity,
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Fig. 5. Epidermal growth factor concentration and ratio of
epidermal growth factor concentfation to total protein
concentration in saliva.
The differences in epidermal growth factor concentra-
tion (μ£/1) demonstrated in saliva of all investigated
collectives are not statistically significant. Referred to
total protein (μg/g protein) it is decreased significantly
in gastric ulcer patients.
All values are means ± SD
** = p < 0.01 compared with healthy controls
the detection limit being 20 ng/1. Changing the incu-
bation time (4 h or overnight) leads to slight shifts of
the detection limit. The increased sensitivity, com-
pared with multiple-step-assay-variants using the
same antibodies, might be explained by the applica-
tion of all immunoreactive components in a single
incubation phase. This means that equilibrium can be
attained in the liquid phase, and is not limited to the
cramped spatial conditions on the wall of microtitre
plates.
The assay System described above proved to be su-
perior to all other ELISA variants that were tried. A
similar assay using rabbit anti-mouse-epidermal
growth factor antibodies against human epidermal
growth factor (immunological cross-reactivity about
50%) was found to be insufficiently sensitive for our
pimposes (detection limit 10 μg/l).
Finally, the polyclonal rabbit anti human epidermal
growth factor antibodies (a kind gift from Dr. Gre-
gory, ICI) served its purpose and yielded the expected
results under the chosen conditions. The sample di-
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lution curves show good linearity up to a dilution of
l: 2. Decreased measured concentrations of epidermal
growth factor in undiluted gastric juice samples are
caused by their low pH values. The measurement of
epidermal growth factor in saliva samples can be
hampered by the fact that the high viscosity can lead
to pipetting inaccuracies. Low pH values disturb our
assay System due to antibody denaturation, but the
immunoreactivity of the epidermal growth factor is
unaffected. These problems were avoided by prelim-
inary dilution of all gastric juice and saliva samples
with 0.15 mol/1 phosphate buffer, pH 7.4.
In order to investigate the role of epidermal growth
factor in gastroduodenal ulcer disease, we analysed
gastric juice and saliva from patients with gastro-
duodenal ulcer and from healthy controls. Although
the discussion of ulcerogenesis emphasizes the impor-
tance of the balance between protective and destruc-
tive factors, the prevailing and exclusive therapeutic
strategy is to diminish or neutralize the acid Output
in both gastric and duodenal ulcers. These therapeutic
concepts acknowledge acid äs the causative agent in
ulcerogenesis in accordance with Schwarzes dictum
"no acid, no ulcer" (13). Nevertheless, the protective
aspects have also been subject to investigations and
especially in the last few years, epidermal growth
factor with its numerous effects has received more
attention from gastreenterologic researchers.
In cultures of numerous epithelial cells epidermal
growth factor increases proliferation and growth and
accelerates differentiation (3). Epidermal growth fac-
tor accelerates healing of cysteamine- and acid-in-
duced ulcers in rat duodenum (14, 15). Surgical re-
moval of salivary glands retards healing of acid-in-
duced ulcers in the rat, whereas exogeneous (oral or
parenteral) epidermal growth factor application de-
monstrates a cimetidine-like healing effect or is effec-
tive in a protective way without affecting acid secre-
tion (16). Epidermal growth factor increases the rate
of DNA/RNA synthesis and elevates the activity of
ornithine decarboxylase which is required for polyam-
ine synthesis (17, 18, 19).
It was first reported by Ohmura that ulcer patients
show decreased amounts of epidermal growth factor
in saliva (9). In this study, it was demonstrated that
epidermal growth factor concentrations in patients
with gastroduodenal ulcer were lower than in normal
subjects, but the results did not differentiate between
gastric and duodenal ulcer. We substantiate one of
Ohmura's results, i.e. that the highest epidermal
growth factor concentrations are present in saliva
samples collected in the morning. Our results, how-
ever, indicate that the epidermal growth factor con-
centration in saliva is not subjected to circadian
rhythm but is dependent on water balance. Since
protein secretion in saliva is adrenergically regulated
in contrast to the chölinergically modulated volume
secretion, a comparative evalüation of the concentra-
tion of epidermal growth factor in saliva alone is
difficult due to its dependence on water balance.
We have considered evaluating the total protein con-
centration and the ratio of epidermal growth factor
concentration to the concentration of total protein äs
a useful reference parameter. In the thirst/fasting tests,
the epidermal growth factor Output and the ratio of
epidermal growth factor concentration to the concen-
tration of total protein were correlated with r > 0.85.
Applying this ratio to patients and controls* a de-
crease of the ratio of epidermal growth factor con-
centration to the concentration of total protein in
saliva was nöticed only in gastric ulcer patients, while
it remained unchanged in all other collectives.
The concentrations of epidermal growth factor in
gastric juice detected by pur ässay systeih are in agree^
ment with data reported by other authors (20). Since
there is a considerable intra- and inter-individual fliic*
tuation in the secretion rate of gastric juice, we de-
termined epidermal growth factor concentrations and
the total volume Output of gastric juice. Decreased
epidermal growth factor concentrations and decreased
epidermal growth factor Outputs iri gastric juice of
patients with gastric ulcer are further indications of
the involvement of epidermal growth factor in gastric
ulcer disease. Whether the decrease of epidermal
growth factor is the cause or the f esült of gastric ulcer
disease remains part of the tantalizing etiologic puzzle
requiring further investigation.
To our knowledge, this is the first confirmation that
the amount of epidermal growth factor in gastrie juice
is decreased in gastric ulcer disease. The fact, that
epidermal growth factor gastric juice concentrations
in patients with duodenal ulcer are within our refer-
ence ränge, however, should not lead to the assump-
tion that epidermal growth factor is not involved in
duodenal ulcer disease. Üsing the working hypothesis
that the decrease öf epidermal growth factor in gastric
juice is connected with or leads to uleer disease, it
would seem to be useful to investigate epidermal
growth factor under the inflüence of anti ulcer drugs
such äs äiitisecretagoga or prostaglandin analogues.
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